Keros Therapeutics Business Summary

Keros Therapeutics, Inc. (KROS) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements and milestone payments, most notably a 2026-active global collaboration with Takeda Pharmaceuticals for elritercept (KER-050). The company’s business is concentrated into two primary segments: Hematology, focused on treating cytopenias in myelodysplastic syndromes and myelofibrosis, and Neuromuscular, centered on its lead candidate rinvatercept (KER-065) for Duchenne muscular dystrophy (DMD). Following a 2025 corporate restructuring that discontinued its pulmonary program to streamline operations, Keros has positioned itself as a specialized leader in modulating the TGF-beta protein superfamily. It competes directly with Sarepta Therapeutics in the DMD space, as well as Merck & Co. and Bristol Myers Squibb in the hematologic and protein therapeutic markets, distinguishing itself through its proprietary library of engineered "ligand traps" designed to restore cellular homeostasis. The leadership team is anchored by Co-founder, President, and CEO Jasbir S. Seehra, Ph.D., a prominent figure in the sector who previously co-founded Acceleron Pharma (acquired by Merck). The executive suite includes Chief Financial Officer Keith Regnante and Chief Scientific Officer Lorena Lerner, Ph.D., who was elevated to the role in August 2025 to spearhead the company’s refined clinical focus. Governance is overseen by Board Chair Jean-Jacques Bienaimé, the former CEO of BioMarin Pharmaceutical, alongside a board featuring representatives from top-tier life science investors including OrbiMed, Venrock, and Foresite Capital. This high-pedigree team is supported by a robust institutional investor base that includes Pontifax and Madison Avenue International, reflecting strong market confidence in the company’s specialized protein engineering platform.